Switching Antibody-Drug Conjugates May Extend Breast Cancer Treatment Benefits
Table of Contents
A new study suggests that breast cancer patients could experience longer-lasting benefits from antibody-drug conjugate (ADC) treatments if physicians strategically rotate between different drug types as resistance develops.
A University of Hawaiʻi Cancer Center study, presented December 10, 2025, at the San Antonio Breast Cancer Symposium, reveals that tumors regain sensitivity to treatment when switched to a follow-up ADC utilizing a different drug class. This research, conducted in laboratory and animal models, offers a promising approach to overcome treatment resistance in breast cancer.
Understanding Antibody-Drug Conjugates and Resistance
ADCs represent a sophisticated approach to cancer therapy, employing an antibody to deliver a potent drug directly to tumor cells.However, many ADCs currently used for breast cancer rely on the same mechanism – targeting DNA – which can lead to cross-resistance. Clinical experience has demonstrated that consecutive use of similar ADCs often yields diminishing returns.
Researchers at the UH Cancer Center discovered that this reduced efficacy may stem from this cross-resistance phenomenon. Their investigation, encompassing both HER2-positive and triple-negative breast cancer models, showed that switching from a DNA-targeting drug to one that blocks cell division effectively restored tumor control. Importantly, this reversal occurred even when the antibody continued to target the same cancer-cell marker.
“A simple takeaway is this: After a cancer progresses on one ADC, choose the next ADC with a different kind of drug,” stated a senior researcher affiliated with the UH Cancer Center Preclinical Core. “This drug-guided approach could help these smart treatments work longer for patients.”
A New Hope for Patients Facing Drug Resistance
The findings offer a meaningful message of hope for patients facing treatment resistance. “These findings show that drug resistance is not necessarily the end of the line for cancer patients,” added the director of the UH Cancer Center.”Choosing the right kind of drug next could help more patients benefit from ADCs.”
The UH Cancer Center is actively collaborating with clinical partners to design studies that personalize ADC selection.These upcoming trials will aim to match the subsequent ADC’s drug payload to the specific mechanisms of resistance observed in each patient’s tumor, with the ultimate goal of prolonging treatment effectiveness.
why: Researchers discovered that breast cancer cells develop resistance to ADCs that use the same drug-delivery mechanism. This is known as cross-resistance.
Who: Researchers at the University of Hawaiʻi Cancer Center conducted the study, and the findings were presented at the San antonio Breast Cancer Symposium on December 10, 2025. The study involved both laboratory and animal models of HER2-positive and triple-negative breast cancer.
What: the study found that switching to an ADC with a different drug payload-specifically, from a DNA-targeting drug to one that blocks cell division-can restore tumor control, even if the antibody remains the same.
How did it end?: The UH Cancer Center is now collaborating with clinical partners to design personalized trials. These trials will aim to match the next ADC’s drug to the specific resistance mechanisms in each patient’s tumor,hoping to extend treatment effectiveness. The research offers hope that drug resistance isn’t a dead end for patients.
